Eleva
Leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
€60.0m | Late VC | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (39 %) | 45 % | (87 %) | 681 % | (58 %) | - | 5 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6805 %) | (4612 %) | (55922 %) | (8856 %) | (16648 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (7450 %) | (5443 %) | (64014 %) | (9480 %) | (18344 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Eleva Biologics is a pioneering startup operating in the pharmaceutical industry. The company collaborates with pharmaceutical partners to develop drug candidates, with a focus on advancing these into clinical stages. Eleva Biologics operates in a unique niche, using Bryophyta, commonly known as moss, to produce biological compounds. This innovative approach allows the company to create complex and demanding proteins, opening up new avenues for unprecedented therapies.
The company's business model is based on partnerships with pharmaceutical companies. Together, they develop complex proteins into potential drugs of the future. Eleva Biologics also works on unlocking the potential of difficult compounds that have previously failed to get expressed. Additionally, the company explores opportunities in other promising fields, developing enzymes and other proteins into clinical stages.
Eleva Biologics' revenue generation strategy is rooted in its technology platform, which remains the property of the company. New individual assets are developed in cooperation with pharmaceutical partners, and each partnership is taken into a newly formed subsidiary. This approach allows the company to monetize its innovative moss-based technology while also fostering collaboration and shared success with its partners.
In summary, Eleva Biologics is a forward-thinking biotech startup that leverages the power of moss to develop new therapies. It operates in a partnership model, working with pharmaceutical companies to bring new drug candidates to the clinical stage.
Keywords: Biotech, Pharmaceutical Partnerships, Drug Development, Clinical Stage, Moss, Biological Compounds, Complex Proteins, Difficult Compounds, Technology Platform, Subsidiaries.